

THANK YOU

DEAR PARTICIPANTS OF THE TREOCAPA STUDY,

As the recruitment period of the study is over, we would like to express our heartfelt thanks to you for your participation and engagement in this research.

With the inclusion of about 800 participants across 14 European countries, we have reached a tremendous goal, allowing us to perform this essential investigation on the effects of paracetamol on the closure of the patent ductus arteriosus in preterm born infants.

Following the enrolment of all study participants, your collected test results will now be analysed over the course of several months and lead to new findings and publications in this field.

We appreciate the time you have invested in this trial and value every single person's contribution, as the medical and scientific knowledge gained from this study will help other newborns.


If you are interested in receiving more information on this study, we invite you to visit and follow our website: <https://treocapa.inserm.fr/>, as any new findings and publications will be communicated there. We anticipate that the final results of the study will be available on the TREOCAPA website in the second quarter of 2025.

On behalf of the entire TREOCAPA study team, we again want to thank you for your participation and contribution to science.

Sincerely,

The TREOCAPA Study Team

Phase III recruitment



Number of NICUs by country

